{"id":1014509,"date":"2026-10-28T07:11:11","date_gmt":"2026-10-28T11:11:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/"},"modified":"2026-10-28T07:11:11","modified_gmt":"2026-10-28T11:11:11","slug":"adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/","title":{"rendered":"Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte\u2019s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer"},"content":{"rendered":"
\n

\n Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte\u2019s TGF\u03b2R2 \u00d7 PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver metastases<\/em>
\n \n <\/p>\n

SAN DIEGO and SUZHOU, China, Oct. 28, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the dosing of the first patient in a Phase 1 study evaluating the combination of muzastotug and INCA33890, Incyte\u2019s TGF\u03b2R2 \u00d7 PD-1 bispecific antibody, in patients with microsatellite stable colorectal cancer (MSS CRC).<\/p>\n

The Phase 1 study is an open-label dose escalation and expansion trial in third-line MSS CRC patients with and without liver metastases who have progressed on prior therapies. Per the terms of the study collaboration first announced in April 2026, Incyte is sponsoring and conducting the study and Adagene is providing clinical supply of muzastotug.<\/p>\n

\u201cBuilding on the clinical activity observed with muzastotug plus pembrolizumab, this study will evaluate whether adding muzastotug to Incyte\u2019s TGF\u03b2R2 \u00d7 PD-1 bispecific can deepen and sustain antitumor responses in MSS colorectal cancer, including patients with liver metastases,\u201d said Peter Luo, Ph.D., Chairman and President of R&D at Adagene. \u201cThe combination brings together muzastotug\u2019s intended intratumoral Treg-depleting activity and INCA33890\u2019s inhibition of two pathways that suppress T-cell function. The study will assess whether these complementary mechanisms can broaden clinical benefit with an acceptable safety profile based on the optimized doses in combination with PD-1. The strength of muzastotug as a potential backbone therapy for multiple indications continues to be recognized through several collaborations with leading biopharmaceutical companies, reflecting its differentiated safety profile relative to legacy CTLA-4 therapies.\u201d<\/p>\n

\n About Adagene<\/strong>\n <\/p>\n

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody\u00ae precision masking technology in multiple approaches at the vanguard of science.<\/p>\n

Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody\u2122, SAFEbody, and POWERbody\u2122 technologies, Adagene\u2019s highly differentiated pipeline features novel immunotherapy programs. The company\u2019s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues.<\/p>\n

Adagene\u2019s lead clinical program, muzastotug (ADG126), is a masked, anti-CTLA-4 SAFEbody with FDA Fast Track designation that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. Muzastotug is currently in Phase 1b\/2 and Phase 2 clinical studies in combination with anti-PD-1 therapy, particularly focused on microsatellite stable (MSS) metastatic colorectal cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi\/multi-specific T-cell engagers.<\/p>\n

For more information, please visit: https:\/\/investor.adagene.com<\/a><\/u>.<\/p>\n

Follow Adagene on WeChat, LinkedIn and X.<\/p>\n

SAFEbody\u00ae is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.<\/p>\n

\n Safe Harbor Statement<\/strong>\n <\/p>\n

This press release contains forward-looking statements, including statements regarding the Phase 1 study of muzastotug (ADG126) in combination with INCA33890, the potential implications of clinical data for patients, and Adagene\u2019s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene\u2019s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene\u2019s drug candidates; Adagene\u2019s ability to achieve commercial success for its drug candidates, if approved; Adagene\u2019s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene\u2019s reliance on third parties to conduct drug development, manufacturing and other services; Adagene\u2019s limited operating history and Adagene\u2019s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene\u2019s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene\u2019s clinical development, commercial and other operations, as well as those risks more fully discussed in the \u201cRisk Factors\u201d section in Adagene\u2019s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.<\/p>\n

\n Investor Contacts:<\/strong>
\n
Raymond Tam
Raymond_tam@adagene.com<\/a><\/p>\n

Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte\u2019s TGF\u03b2R2 \u00d7 PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver metastases SAN DIEGO and SUZHOU, China, Oct. 28, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the dosing of the first patient in a Phase 1 study evaluating the combination of muzastotug and INCA33890, Incyte\u2019s TGF\u03b2R2 \u00d7 PD-1 bispecific antibody, in patients with microsatellite stable colorectal cancer (MSS CRC). The Phase 1 study is an open-label dose escalation and expansion trial in third-line MSS CRC patients with and without liver metastases who have … <\/p>\n

Continue reading “Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte\u2019s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1014509","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAdagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte\u2019s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte\u2019s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte\u2019s TGF\u03b2R2 \u00d7 PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver metastases SAN DIEGO and SUZHOU, China, Oct. 28, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the dosing of the first patient in a Phase 1 study evaluating the combination of muzastotug and INCA33890, Incyte\u2019s TGF\u03b2R2 \u00d7 PD-1 bispecific antibody, in patients with microsatellite stable colorectal cancer (MSS CRC). The Phase 1 study is an open-label dose escalation and expansion trial in third-line MSS CRC patients with and without liver metastases who have … Continue reading "Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte\u2019s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-28T11:11:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTg2NyM3OTEyNTA0IzIyMDQ2ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte\u2019s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer\",\"datePublished\":\"2026-10-28T11:11:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\\\/\"},\"wordCount\":881,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTg2NyM3OTEyNTA0IzIyMDQ2ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\\\/\",\"name\":\"Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte\u2019s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTg2NyM3OTEyNTA0IzIyMDQ2ODE=\",\"datePublished\":\"2026-10-28T11:11:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTg2NyM3OTEyNTA0IzIyMDQ2ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MTg2NyM3OTEyNTA0IzIyMDQ2ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte\u2019s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte\u2019s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte\u2019s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer - Market Newsdesk","og_description":"Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte\u2019s TGF\u03b2R2 \u00d7 PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver metastases SAN DIEGO and SUZHOU, China, Oct. 28, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the dosing of the first patient in a Phase 1 study evaluating the combination of muzastotug and INCA33890, Incyte\u2019s TGF\u03b2R2 \u00d7 PD-1 bispecific antibody, in patients with microsatellite stable colorectal cancer (MSS CRC). The Phase 1 study is an open-label dose escalation and expansion trial in third-line MSS CRC patients with and without liver metastases who have … Continue reading \"Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte\u2019s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-28T11:11:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTg2NyM3OTEyNTA0IzIyMDQ2ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte\u2019s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer","datePublished":"2026-10-28T11:11:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/"},"wordCount":881,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTg2NyM3OTEyNTA0IzIyMDQ2ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/","name":"Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte\u2019s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTg2NyM3OTEyNTA0IzIyMDQ2ODE=","datePublished":"2026-10-28T11:11:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTg2NyM3OTEyNTA0IzIyMDQ2ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MTg2NyM3OTEyNTA0IzIyMDQ2ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incytes-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte\u2019s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1014509","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1014509"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1014509\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1014509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1014509"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1014509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}